KR20020040532A - Antioxidative drink excellent in inhibiting the side effects according to anticancer therapy and the method of manufacturing the same - Google Patents
Antioxidative drink excellent in inhibiting the side effects according to anticancer therapy and the method of manufacturing the same Download PDFInfo
- Publication number
- KR20020040532A KR20020040532A KR1020010024720A KR20010024720A KR20020040532A KR 20020040532 A KR20020040532 A KR 20020040532A KR 1020010024720 A KR1020010024720 A KR 1020010024720A KR 20010024720 A KR20010024720 A KR 20010024720A KR 20020040532 A KR20020040532 A KR 20020040532A
- Authority
- KR
- South Korea
- Prior art keywords
- antioxidant
- red ginseng
- saponin
- weight
- low molecular
- Prior art date
Links
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 57
- 230000000694 effects Effects 0.000 title claims abstract description 29
- 238000011319 anticancer therapy Methods 0.000 title claims description 15
- 230000002401 inhibitory effect Effects 0.000 title claims description 15
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 40
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 35
- 229930182490 saponin Natural products 0.000 claims abstract description 34
- 150000007949 saponins Chemical class 0.000 claims abstract description 34
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 29
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000001301 oxygen Substances 0.000 claims abstract description 11
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 11
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 10
- 229930195712 glutamate Natural products 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 239000011259 mixed solution Substances 0.000 claims abstract description 3
- 239000008213 purified water Substances 0.000 claims abstract description 3
- 235000013361 beverage Nutrition 0.000 claims description 29
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 abstract description 5
- 239000000654 additive Substances 0.000 abstract description 2
- 230000000996 additive effect Effects 0.000 abstract description 2
- 238000011394 anticancer treatment Methods 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 description 32
- 235000017709 saponins Nutrition 0.000 description 27
- 150000003254 radicals Chemical class 0.000 description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 7
- 241000208340 Araliaceae Species 0.000 description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 230000007760 free radical scavenging Effects 0.000 description 6
- 235000008434 ginseng Nutrition 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- -1 hydroxyl radicals Chemical class 0.000 description 5
- 150000007965 phenolic acids Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940124650 anti-cancer therapies Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002180 anti-stress Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940094952 green tea extract Drugs 0.000 description 2
- 235000020688 green tea extract Nutrition 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- GBCAVSYHPPARHX-UHFFFAOYSA-M n'-cyclohexyl-n-[2-(4-methylmorpholin-4-ium-4-yl)ethyl]methanediimine;4-methylbenzenesulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.C1CCCCC1N=C=NCC[N+]1(C)CCOCC1 GBCAVSYHPPARHX-UHFFFAOYSA-M 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- UPPXMONNNGGKMB-UHFFFAOYSA-N 3-O-(alpha-L-rhamnopyranosyl-(1->2)-beta-D-glucopyranosyl-(1->2)-beta-D-glucopyranosyl)spergulagenic acid Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(CO)C(O)C2O)OC2C(C3C(C4C(C5(CCC6(CCC(C)(CC6C5=CC4)C(O)=O)C(O)=O)C)(C)CC3)(C)CC2)(C)C)OC(CO)C(O)C1O UPPXMONNNGGKMB-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000008047 antioxidant nutrient Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229940005494 general anesthetics Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
Landscapes
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
Description
본 발명은 항암요법에 따른 부작용 억제 효과를 갖는 항산화 음료 및 그 제조 방법에 관한 것으로서 보다 상세하게는 항산화 활성을 갖는 저분자화된 홍삼 사포닌과 활성산소 억제물질인 글루메이트(Glumate, GMT)를 포함하여 제조함으로써 항산화 활성이 우수한 항암요법에 따른 부작용 억제 효과를 갖는 항산화 음료 및 그 제조 방법에 관한 것이다.The present invention relates to an antioxidant drink having a side effect inhibitory effect according to anticancer therapy and a method for preparing the same, and more particularly, including low molecular weight red ginseng saponin having antioxidant activity and glutamate (Glumate, GMT) which is an active oxygen inhibitor. The present invention relates to an antioxidant beverage having a side effect inhibiting effect according to an anticancer therapy having excellent antioxidant activity, and a method for producing the same.
자유 라디칼(Free radical)은 하나 이상의 짝을 이루지 못한 전자를 가지고 있는 분자로서 다른 분자로부터 전자를 빼앗아 안정화하려는 특성을 지니고 있다. 또한자유 라디칼은 수명이 수천 분의 일초 정도로 짧아 매우 불안정하고 공격적이며 강한 산화력을 가지고 있다. 자유 라디칼의 대부분은 활성 산소종(Reactive Oxygen Species)으로, 그 종류로는 히드록실 라디칼(hydroxyl radical), 슈퍼옥사이드 라디칼(superoxide radical), 일중항 산소(singlet oxygen) 및 과산화수소(H2O2)와 지질과산화에 따라 발생하는 알콕실 라디칼(alkoxyl radical) 등이 있다.Free radicals are molecules that have one or more unpaired electrons and have the property of stabilizing electrons from other molecules. Free radicals are also very unstable, aggressive, and strong in oxidative power, with lifespans as short as thousands of seconds. Most of the free radicals are reactive oxygen species, which include hydroxyl radicals, superoxide radicals, singlet oxygen, and hydrogen peroxide (H 2 O 2 ). And alkoxyl radicals generated by lipid peroxidation.
체내에서 이러한 활성 산소종을 발생시키는 통상의 인자로서, 스트레스, 알콜, 과산화물, 약물 등이 공지되어 있다.As a common factor for generating such reactive oxygen species in the body, stress, alcohols, peroxides, drugs and the like are known.
한편, 현재 전 세계적으로 수천만 명이 넘는 암환자들이 있으며 이들에게 적용되는 항암 요법이 모두 심각한 부작용을 나타내며 그 부작용들 또한 공통적으로 자유 라디칼에 기인하는 것으로 알려져 있다.On the other hand, there are more than tens of millions of cancer patients all over the world, and all of the anticancer therapies applied to them are known to have serious side effects, which are commonly known to be caused by free radicals.
대표적인 항암 요법과 그 부작용을 살펴보면, 먼저 방사선 요법으로 X선 및 α, β, γ선 등에 의한 방사선 조사에 의한 DNA의 분해, 세포의 사멸, 증식 능력의 소실, 돌연변이, 종양세포의 형질변이 등 많은 화학적 변화를 가져온다. 또한, 외과요법으로 수술요법을 시행시에 전신 또는 국소마취제, 지혈제, 혈액 응고 방지제 및 진통제의 병용투여에 따른 약물에 의한 활성 산소의 발생(OH·, NO2등)과 대사 과정의 일시적 불균형 및 출혈에 따른 일시적 빈혈 등 산화적 스트레스(Oxidative stress)에 의한 체내의 활성 산소 대량 발생으로 피로감, 백혈구 수치의 저하, 면역력 저하, 혈소판 감소 등의 부작용을 가져올 수 있다. 화학 요법으로 대표적인 제암제로서 아드리아마이신(adriamycin), 블레오마이신(bleomycin),마이토마이신(mitomycin), 시스플라틴(cisplatin) 등이 있으며, 이들의 장기 투여시 DNA의 합성과 세포분열의 억제 및 세포막 손상 등 DNA 손상으로 인한 가역적 또는 비가역적 부작용을 유발한다. 상술한 바와 같이 대부분의 항암 요법은 모두 심각한 부작용을 나타내며 그 부작용의 작용 기전에서 공통적으로 자유 라디칼이 관여되어 있는 것으로 알려져 있다.Representative anti-cancer therapies and their side effects, first of all, radiation therapy, such as X-ray and radiation by irradiation with α, β, γ-rays, DNA degradation, cell death, loss of proliferative capacity, mutation, mutation of tumor cells, etc. Brings chemical changes. In addition, the generation of free radicals (OH, NO 2, etc.) and metabolic processes due to the combination of general or local anesthetics, hemostatic agents, anticoagulants, and analgesics during surgical therapy. Massive generation of free radicals due to oxidative stress such as transient anemia caused by bleeding can cause side effects such as fatigue, lowering white blood cell count, lowering immunity, and reducing platelets. Examples of chemotherapy agents include adriamycin, bleomycin, mitomycin, and cisplatin, which inhibit DNA synthesis, cell division, and cell membrane damage during long-term administration. And can cause reversible or irreversible side effects from DNA damage. As described above, most anti-cancer therapies all have serious side effects, and it is known that free radicals are commonly involved in the mechanism of action of the side effects.
이러한 자유 라디칼에 의한 손상으로부터 스스로를 보호하기 위해 체내에는 일련의 산화 보호 시스템을 갖추고 있다. 이러한 보호 시스템으로 슈퍼옥사이드 디스뮤타즈(superoxide dismutase; SOD), 카탈라제(catalase) 등의 효소와 α-토코페롤(α-Tocopherol, Vitamin E), β-카로틴(β-Carotene), 아스코르빈산(Ascorbic acid, Vitamin C) 및 글루타치온(Glutathione)과 같은 지용성 및 수용성 항산화제 또는 라디칼 소거제들이 포함된다.To protect itself from damage caused by these free radicals, the body is equipped with a series of oxidative protection systems. Such protective systems include enzymes such as superoxide dismutase (SOD) and catalase, and α-tocopherol (vitamin E), β-carotene and ascorbic acid (ascorbic acid). fat-soluble and water-soluble antioxidants or radical scavengers such as acid, Vitamin C) and glutathione.
그러나, 현대인들은 대기환경 오염, 불건전한 식생활, 자외선 노출, 스트레스, 병들의 유해환경에 노출되어 생체내의 라디칼 소거 시스템과의 불균형으로 여러 라디칼들에 의한 산화적 스트레스(oxidative stress)를 충분히 소거하기 어려운 형편이므로 이러한 시스템을 정상적으로 작용시키기 위해 항산화 영양 성분을 충분히 섭취하는 것이 중요하다. 또한, 자체로써 체내에 생성된 활성 산소종을 제거하여 자유 라디칼에 의한 각종 질병 및 부작용을 막을 수 있는 항산화 식품의 개발이 크게 요구되고 있다.However, modern people are exposed to air pollution, unhealthy diet, UV exposure, stress, and harmful environment of illness, and it is difficult to eliminate oxidative stress caused by various radicals due to imbalance with the radical scavenging system in vivo. As a matter of fact, it is important to get enough antioxidant nutrients in order to function properly. In addition, the development of antioxidant foods that can prevent various diseases and side effects caused by free radicals by removing the active oxygen species generated in the body by itself.
한편 인삼은 예로부터 대표적인 자양강장제로 널리 사용되어 온 식물로서, 일반적으로 재배하여 채취한 그대로의 수삼, 수삼을 상온에서 건조시킨 백삼 또는 수삼을98∼100℃에서 가열 처리하여 제조되는 홍삼의 형태로 사용되고 있다. 인삼의 성분과 약효에 대한 많은 연구결과가 보고되어 있는데, 현재까지 알려진 인삼의 약효로는 노화억제, 항동맥경화 및 고지혈증 개선, 간기능항진, 방사선장애 제거, 면역증강, 항혈전, 뇌기능항진, 항스트레스, 혈당강하, 혈압강하 또는 항암효과 등이 있다. 특히 홍삼의 사포닌 성분인 홍삼 토탈 사포닌(total saponine)은 자유 라디칼에 의한 손상이나 지질과산화를 감소시키며 생체계에서 산소에 의해 일어나는 손상을 차단하는 항산화 활성을 갖는 것으로 알려져 있으나 그 효능에 관한 직접적인 연구는 아직까지 미비한 상태이다.On the other hand, ginseng is a plant that has been widely used as a representative nourishing tonic since ancient times, and is generally in the form of red ginseng prepared by heat-treating white ginseng or ginseng dried at room temperature, as it is grown and harvested at room temperature. It is used. Many researches on the components and efficacy of ginseng have been reported.The known effects of ginseng are anti-aging, anti-arteriosclerosis and hyperlipidemia, liver function enhancement, radiation disorder removal, immune enhancement, antithrombosis, brain hyperactivity. , Antistress, lowering blood sugar, lowering blood pressure or anticancer effect. In particular, red ginseng saponins, total saponins, are known to have antioxidant activity that reduces damage caused by free radicals or lipid peroxidation and blocks oxygen-induced damage in the biological system. It is still incomplete.
이에 본 발명은 항산화 활성을 갖는 저분자화된 홍삼 사포닌과 활성산소 억제물질인 글루메이트를 포함하여 제조된 항산화 활성이 우수한 항암요법에 따른 부작용 억제 효과를 갖는 항산화 음료를 제공하는데 그 목적이 있다.Accordingly, an object of the present invention is to provide an antioxidant beverage having a low side effect according to an anticancer therapy having excellent antioxidant activity, including low molecular weight red ginseng saponin and an active oxygen inhibitor glutmate having antioxidant activity.
본 발명의 다른 목적은 저분자화된 홍삼 사포닌, 글루메이트, 항산화 기능성을 향상시키는 보조성분 및 향이나 맛을 가미하는 보조제를 일정한 조성비로 배합하여 상기의 항산화 음료를 제조하는 방법을 제공함에 있다.Another object of the present invention is to provide a method for producing the antioxidant drink by combining a low molecular weight red ginseng saponin, glutate, an auxiliary component to improve antioxidant functionality and an adjuvant to add flavor or taste.
본 발명의 또 다른 목적은 본 발명에 따른 항산화 음료를 지속적으로 음용함으로써 전체적인 면역력의 증강으로 자유 라디칼로부터 기인하는 여러 질병과 부작용을 방지하고 특히, 자유 라디칼이 주요 원인인 항암요법 부작용을 억제할 수 있는 항산화 음료를 제공하는데 있다.Another object of the present invention is to continuously drink the antioxidant drink according to the present invention to prevent various diseases and side effects resulting from free radicals by strengthening the overall immunity, and in particular, to suppress the anticancer therapy side effects, which are the main cause of free radicals To provide an antioxidant drink.
도1은 본 발명에 따른 항암요법에 따른 부작용 억제 효과를 갖는 항산화 음료의 자유 라디칼 소거능을 나타낸 그래프이다.1 is a graph showing the free radical scavenging ability of the antioxidant beverage having the side effect inhibitory effect according to the anticancer therapy according to the present invention.
도2는 본 발명에 따른 항산화 음료의 항산화능에 있어서 글루메이트(GMT)의 역할을 나타낸 그래프이다.Figure 2 is a graph showing the role of glutmate (GMT) in the antioxidant capacity of the antioxidant beverage according to the present invention.
상기 목적을 달성하기 위한 본 발명에 따른 항암요법에 따른 부작용 억제 효과를 갖는 항산화 음료는 항산화 활성을 갖는 저분자화된 홍삼 사포닌과 활성산소 억제 효과를 갖는 글루메이트를 포함하는 것을 특징으로 한다.Antioxidant beverage having a side effect inhibitory effect according to the anticancer therapy according to the present invention for achieving the above object is characterized in that it comprises a low molecular weight red ginseng saponin having antioxidant activity and a glutate having an active oxygen inhibitory effect.
상기 홍삼 사포닌은 1 내지 15 중량%, 글루메이트는 1 내지 6 중량%를 함유하는 것을 특징으로 한다.The red ginseng saponin is 1 to 15% by weight, glutamate is characterized in that it contains 1 to 6% by weight.
본 발명에 따른 항암요법에 따른 부작용 억제 효과를 갖는 항산화 음료의 제조방법은 항산화 활성을 갖는 홍삼 사포닌을 효소 처리하여 저분자화하는 단계, 상기 저분자화된 홍삼 사포닌 1 내지 15 중량%에 글루메이트 1 내지 6 중량%, 항산화 기능성을 향상시키는 보조성분 및 향이나 맛을 가미하는 보조제를 혼합하여 정제수에 완전 용해시키는 단계 및 상기 혼합용액을 살균 밀봉하여 방냉하고 반복 여과 처리하는 단계를 포함하는 것을 특징으로 한다.The method for preparing an antioxidant beverage having the side effect inhibitory effect according to the anticancer therapy according to the present invention comprises the steps of low molecular weight by enzyme treatment of red ginseng saponin having antioxidant activity, 1 to 15% by weight of the low molecular weighted red ginseng saponin 6 wt%, by mixing the auxiliary component to improve the antioxidant function and the additive to add aroma or taste to completely dissolved in purified water and the step of sterilizing and sealing the mixed solution to cool and repeat filtration.
인삼 특유의 약리활성 사포닌인 진세노사이드 유도체들은 다마란계의 트리테르페노이드인 프로토파낙사다이올과 프로토파낙사트라이올의 알코올성 수산기에 글루코오스, 람노스, 자일로스 또는 아라비노스와 같은 당류가 결합한 화합물들로서 그 분자량이 매우 커서 체내 흡수가 용이하지 못하다. 따라서 본 발명에서는 이러한 고분자 사포닌의 체내 흡수를 증가시킬 수 있도록 사포닌을 효소처리에 의해 저분자화시켜 사용하였다. 이 때 효소는 Deerland Cellulase 4000을 사용하며 홍삼 추출물에 0.01% 내지 0.1 중량%를 가하여 홍삼 사포닌을 저분자화하여 체내 흡수를 용이하게 함으로써 항산화 활성을 높이는 역할을 한다.Ginsenoside derivatives, ginseng's unique pharmacologically active saponins, contain sugars such as glucose, rhamnose, xylose or arabinose in the alcoholic hydroxyl groups of the protoparnasadiol and the protoparnasatriol, which are triterpenoids of the dimaran series. As the combined compounds, their molecular weight is so large that absorption into the body is not easy. Therefore, in the present invention, saponins were used in a low molecular weight by enzymatic treatment so as to increase the absorption of the polymer saponins in the body. At this time, the enzyme uses Deerland Cellulase 4000 and adds 0.01% to 0.1% by weight to red ginseng extract to lower the red ginseng saponin to facilitate the absorption in the body, thereby enhancing antioxidant activity.
본 발명에 따른 항암요법에 따른 부작용 억제 효과를 갖는 항산화 음료의 제조 방법에서 사용한 글루메이트는 미당(米糖)과 대두를 알칼리 발효법으로 추출한 것으로 유해 산소 저해제(superoxide dismutase, SOD)작용, 혈압 억제 작용, 항산화 효소 SOD1의 작용에 의하여 생산된 과산화수소를 물과 산소로 분해하는 카탈라제 작용 및 항스트레스 작용도 있는 것으로 알려져 있으며 특히, 활성 산소 및 자유 라디칼인 OH·, H2O2,1O2등의 소거작용에 탁월한 효과가 있는 것으로 알려져 있다. 본 발명에서는 항산화 활성을 증가시키기 위해 일본 동양발효(주)에서 발명한 '미배아, 대두발효 추출물'인 글루메이트 5배 농축액인 GMT-SOD가 사용될 수 있으며 이는 곡류, 종자류 중에 피틴(Phytin)함량이 가장 많은 것을 원료로 호알칼리성 미생물에 의해 발효시켜 제조된 것이다.Glumate used in the preparation method of antioxidant drink having the side effect suppression effect according to the anticancer therapy according to the present invention is extracted from microsaccharides and soybeans by alkaline fermentation, harmful oxygen inhibitor (superoxide dismutase (SOD) action, blood pressure inhibitory effect In addition, catalase and antistress are known to decompose hydrogen peroxide produced by the action of the antioxidant enzyme SOD1 into water and oxygen. In particular, active oxygen and free radicals such as OH ·, H 2 O 2 and 1 O 2 It is known to have an excellent effect on scavenging action. In the present invention, in order to increase the antioxidant activity, GMT-SOD, a glutamate 5-fold concentrate, which is an 'embryonic, soybean fermentation extract' invented by Dongyang Fermentation Co., Ltd., Japan, can be used. Most of them are produced by fermentation by alkalescent microorganisms as raw materials.
상기의 저분자화된 홍삼 사포닌과 글루메이트에 보조성분 및 보조제가 첨가될 수 있다. 이 때 보조성분은 주성분에 부가하여 항산화 기능성을 향상시키는 것으로서 항산화 활성을 갖는 녹차 추출물 및 비타민류로서 비타민 C, 비타민 B1, 비타민 B2등이 사용될 수 있다. 보조제는 향이나 맛을 가미하는 것으로서 예를 들면 허브향, 올리고당, 구연산나트륨 및 C.M.C 등이 사용될 수 있다.Supplementary ingredients and auxiliaries may be added to the low molecular weight red ginseng saponin and glutate. In this case, the auxiliary ingredient may be used as vitamin C, vitamin B 1 , vitamin B 2 , and the like as green tea extract and vitamins having antioxidant activity as an antioxidant function in addition to the main ingredient. Adjuvants add flavors or flavors, for example, herbal flavors, oligosaccharides, sodium citrate, CMC and the like can be used.
이러한 성분을 혼합하여 항산화 음료를 만드는 단계에서 홍삼 사포닌의 양은 전체 음료조성물 중에 1 내지 15 중량%, 글루메이트는 1 내지 6 중량% 범위내에서 사용하는 것이 바람직하다. 이때의 홍삼 사포닌과 글루메이트의 양이 1 중량% 보다 적을 경우는 항산화 활성에 있어서 뚜렷한 효과를 나타내지 못하며 양이 증가할수록 항산화능은 증가한다. 그러나, 홍삼 사포닌의 양이 15 중량%를 초과하는 경우는 홍삼 특유의 쓴맛으로 인하여 음용하기에 적합하지 못하며 글루메이트는 고가의 상품으로 6 중량%이하의 사용에서도 우수한 항산화 활성을 보여준다. 본 발명에 따른 항산화 음료의 바람직한 성분비를 다음의 표1에 나타내었다.The amount of red ginseng saponin in the step of mixing these ingredients to make an antioxidant drink is preferably used in the range of 1 to 15% by weight, glutamate 1 to 6% by weight in the total beverage composition. If the amount of red ginseng saponin and glutate is less than 1% by weight, it does not have a definite effect on the antioxidant activity and the antioxidant activity increases as the amount increases. However, when the amount of red ginseng saponin exceeds 15% by weight, it is not suitable for drinking due to the bitter taste peculiar to red ginseng, and glutmate is an expensive product and shows excellent antioxidant activity even under 6% by weight. Preferred component ratios of the antioxidant beverage according to the present invention are shown in Table 1 below.
표1 항산화 음료의 조성표Table 1 Composition of Antioxidant Beverage
상기의 성분들을 혼합한 용액을 살균, 밀봉하여 방냉한 후 여과하는 단계에서 10μ마이크로 필터를 사용하여 4회 이상 반복하여 여과함으로써 음료 혼합물에 남아 있을 수 있는 불순물을 최대한 제거한다.In the step of sterilizing, sealing and cooling the solution in which the above components are mixed, the filter is repeatedly filtered four or more times using a 10 μ microfilter to remove impurities that may remain in the beverage mixture.
이하에서 본 발명에 의한 음료의 제조 방법과 효과를 실시예를 통하여 더욱 상세히 설명하나, 본 발명의 범위가 하기 실시예만으로 한정되는 것은 아니다.Hereinafter, the method and effect of preparing the beverage according to the present invention will be described in more detail with reference to Examples, but the scope of the present invention is not limited to the following Examples.
실시예 1Example 1
홍삼 500g을 1L의 에탄올에 넣어 70℃에서 초음파장치로 5시간 추출하여 여과시키는 방법을 3회 반복하였다. 2.5L 정도의 홍삼추출물을 감압 농축기로 1.5L까지 감압 농축한 홍삼추출물에 Deerland Cellulase 4000을 0.1% 첨가하고 60℃의 인큐베이터에 넣어 6시간 반응시켰다. 12시간 후 즉시 100℃ 항온수조에서 10분간 열처리하여 효소 불활성화를 행하며 그 직후 3,500 ×g에서 20분간 원심분리하고 상징액을 취하여 저분자화된 홍삼 사포닌을 제조하였다.500 g of red ginseng was added to 1 L of ethanol, and the method of extracting and filtering by ultrasonic apparatus at 70 ° C. for 5 hours was repeated three times. The red ginseng extract of about 2.5L was depressurized to 1.5L with a decompression concentrator, and 0.1% of Deerland Cellulase 4000 was added to the red ginseng extract. After 12 hours, the enzyme was inactivated by heat treatment for 10 minutes in a 100 ° C. constant temperature water bath, followed by centrifugation at 3,500 × g for 20 minutes, and the supernatant was taken to prepare low molecular weight red ginseng saponin.
실시예 2Example 2
정제수에 실시예1에서 제조된 저분자화된 홍삼 사포닌, 글루메이트, 녹차 추출물, 올리고당, 비타민C, 비타민 B1염산염, 비타민 B2, 허브향, 구연산나트륨, C.M.C를 아래 표2의 비율로 혼합하여 80℃에서 완전히 용해시킨 후 95℃에서 30분간 살균한 후 밀봉하여 18시간 방냉하였다.The low molecular weight red ginseng saponin, glutmate, green tea extract, oligosaccharide, vitamin C, vitamin B 1 hydrochloride, vitamin B 2 , herbal flavor, sodium citrate, and CMC prepared in Example 1 were mixed in the ratio of Table 2 below. After dissolving completely at 80 ° C., the solution was sterilized at 95 ° C. for 30 minutes, sealed, and cooled for 18 hours.
표2 실시예 2에 따른 항산화 음료의 조성표Table 2 Composition table of antioxidant drink according to Example 2
방냉시킨 용액을 10μ마이크로 필터로 수회 반복 여과하여 다갈색의 맑은 액상을 얻은 후 정량씩 충진 밀봉하였다. 이 액상을 95∼100℃에서 30분간 후살균하고 포장하여 본 제품의 완제품을 제조하였다.The cooled solution was repeatedly filtered several times with a 10 占 micro filter to obtain a dark brown clear liquid, which was filled and sealed by quantitation. The liquid was then sterilized and packaged at 95 to 100 ° C. for 30 minutes to prepare a finished product of this product.
실시예 3Example 3
실시예 1에서 제조된 저분자화된 홍삼 사포닌에 GMT-SOD를 제거한 것을 제외하고는실시예 2와 동일한 성분과 조성비로 혼합하고 동일한 방법으로 글루메이트가 제거된 홍삼 사포닌 음료를 제조하였다.Except that GMT-SOD was removed from the low molecular weight red ginseng saponin prepared in Example 1, red ginseng saponin was prepared by mixing the same components and compositions as in Example 2 and removing the glutate in the same manner.
본 발명의 실시예에 따라 제조된 저분자화된 홍삼 사포닌과 글루메이트를 포함한 음료에 대하여 관능검사 및 식품공전규격 검사방법에 따라 안정성 시험을 실시하였다. 시험 방법은 포장제품을 기준으로 하여 전기 항온기(40℃)에서 60일간 보관중인 제품의 색상, 풍미, 이미, 이취를 변화에 따른 관능검사원 5명이 검사하여 성상을 5점 대비표 중 3.0이상이면 품질변화가 거의 없는 제품으로 소비자에게 만족도를 줄 수 있고 상품성이 있는 제품으로 식품공전의 규격대로 검사하여 그 결과를 아래 표3에 나타내었다.Stability test was performed according to the sensory test and food standards test method for a beverage containing low molecular weight red ginseng saponin and glutate prepared according to an embodiment of the present invention. The test method is based on the packaged product and five sensory inspectors inspecting the color, flavor, and odor of the product stored in an electric thermostat (40 ℃) for 60 days. It is a product with little change, which can give consumers satisfaction, and it is a product with merchandise, and the result is shown in Table 3 below.
표3Table 3
표3의 검사결과 본 발명의 실시예에 따라 제조된 음료는 18개월 이상 성상이나 일반세균 및 대장균에 대하여 모두 그 안정성이 입증되었다.As a result of the test of Table 3, the beverage prepared according to the embodiment of the present invention has been proved its stability against the appearance and general bacteria and E. coli over 18 months.
본 발명의 실시예에 따라 제조된 음료에 대하여 항산화능, 즉 자유 라디칼 소거능을 다음과 같이 측정하였다. 사용된 방법은 1,1-Diphenyl-2-Pycryl-Hydrazyl(DPPH)방법으로 수행하였다. DPPH는 비교적 안정한 자유 라디칼로서 라디칼 상태로 존재시 517㎚에서 최대 흡광도를 나타내며 소거되면 흡광성을 잃는다. DPPH는 미국 시그마(Sigma)사의 것을 사용하였으며 에탄올 50㎖에 0.006g을 녹인 후 물 50㎖를 가하여 0.006%용액을 만들었다. 이 DPPH 용액을 3㎖를 취하여 시험관에 넣은 후 본 발명의 실시예 2에 따른 음료를 0.05㎖에서 0.55㎖까지 각 농도별로 취하여 잘 섞어 실온에서 15분간 방치한 후 517㎚에서의 흡광도를 측정하였다. 이때, 대조군으로는 본 발명에 따른 음료 대신 물을 넣은 것을 사용하였다. 시료의 흡광도와 대조군의 흡광도를 비교하여 도1에 나타내었다.Antioxidant activity, ie free radical scavenging activity, was measured as follows for the beverages prepared according to the embodiment of the present invention. The method used was performed by the 1,1-Diphenyl-2-Pycryl-Hydrazyl (DPPH) method. DPPH is a relatively stable free radical which, when present in the radical state, exhibits maximum absorbance at 517 nm and loses absorbance when erased. DPPH was used by Sigma, USA, and 0.006 g of 50 ml of ethanol was dissolved, and 50 ml of water was added to make a 0.006% solution. After taking 3 ml of this DPPH solution into a test tube, the beverage according to Example 2 of the present invention was taken from 0.05 ml to 0.55 ml for each concentration, mixed well, and left at room temperature for 15 minutes, and the absorbance at 517 nm was measured. At this time, the control was used to put water instead of the beverage according to the present invention. The absorbance of the sample is compared with that of the control group and is shown in FIG. 1.
도1에서 본 발명에 따른 음료의 자유 라디칼 소거능 즉, 항산화능을 나타내었다. 자유 라디칼 소거능은 과산화 지질산화의 연쇄 반응에 관여하는 산화성 자유 라디칼에 전자를 제공하여 연쇄 반응을 정지시켜 산화를 억제하므로 항산화능의 척도가 된다. 따라서, 도1에서 알 수 있듯이, 본 발명에 따른 홍삼 사포닌에 글루메이트를 첨가한 음료의 자유 라디칼 소거능을 측정한 결과 시료를 넣지 않은 대조군에 비하여 적은 양에서도 2.5배 내지 3.0배 우수한 항산화능을 나타냄을 알 수 있다.1 shows free radical scavenging ability, that is, antioxidant capacity, of the beverage according to the present invention. The free radical scavenging ability provides an electron to the oxidative free radicals involved in the chain reaction of lipid peroxide, thereby stopping the chain reaction and inhibiting oxidation, thus becoming a measure of antioxidant capacity. Therefore, as can be seen in Figure 1, the free radical scavenging ability of the beverage added glutamate to red ginseng saponin according to the present invention showed a 2.5 to 3.0 times better antioxidant capacity than a control without a sample It can be seen.
본 발명의 실시예에 따른 음료에 대한 항산화능에 있어서 글루메이트의 역할을 알아보기 위하여 홍삼 사포닌과 글루메이트를 포함한 실시예 2에서 제조된 음료와 글루메이트를 제거한 실시예 3에서 제조된 시료에 대하여 아래와 같은 실험을 실시하였다. 본 발명에 따른 음료를 시료로 0.2㎖ 취하여 2% 탄산나트륨(Na2CO3) 2.0㎖를 넣어 2분간 잘 섞은 후 발색시약으로 Folin-ciocalpeu's reagent를 0.2㎖(50%) 넣어서 잘 섞어서 실온에 방치한 후 750㎚에서 흡광도를 측정하여 항산화 활성을 나타내는 성분인 토탈 페놀산(total phenolic acid)의 양을 계산하였다. 이때 시료는0.2㎖에서 17㎖까지 각 농도별로 취하였으며 표준시료(standard)로 chlorogenic acid를 사용하였다. 대조군으로 실시예 3에서 제조된 시료를 동일한 농도별로 취하여 흡광도를 측정하여 시료를 측정한 값과 비교하여 그 결과를 도2에 나타내었다.In order to determine the role of glutmate in the antioxidant capacity of the beverage according to an embodiment of the present invention for the sample prepared in Example 3, in which the beverage and glutate prepared in Example 2 including red ginseng saponin and glutate were removed, The same experiment was conducted. Take 0.2 ml of the beverage according to the present invention as a sample, add 2.0 ml of 2% sodium carbonate (Na 2 CO 3 ), mix well for 2 minutes, add 0.2 ml (50%) of Folin-ciocalpeu's reagent as a color development reagent, and leave it at room temperature. After measuring the absorbance at 750nm to calculate the amount of total phenolic acid (total phenolic acid) that is a component showing antioxidant activity. At this time, samples were taken at each concentration from 0.2ml to 17ml and chlorogenic acid was used as a standard sample. As a control, the samples prepared in Example 3 were taken at the same concentration, and the absorbance was measured. The results are shown in FIG.
도2에서 본 발명에 따른 음료의 항산화능에 있어서 글루메이트의 역할을 나타낸 것으로 본 발명에 따른 음료와 글루메이트를 제거한 음료에 대해서 항산화능을 나타내는 성분인 토탈 페놀산의 양을 측정하였다. 도2에서 알 수 있듯이, 본 발명에 따른 음료는 토탈 페놀산의 양이 16.94㎎/㎖인 반면 SOD가 제거된 시료의 토탈 페놀산의 양은 1.99㎎/㎖를 나타내어 항산화능에 있어서 홍삼 사포닌 뿐 아니라 글루메이트의 역할 또한 중요함을 알 수 있다. 즉, 본 발명에서는 홍삼 사포닌과 글루메이트를 포함하여 우수한 항산화능을 나타내는 음료를 개발하였다.Figure 2 shows the role of glutmate in the antioxidant capacity of the beverage according to the present invention was measured for the amount of total phenolic acid which is a component showing the antioxidant activity for the beverage and the beverage without glutamate according to the present invention. As can be seen in Figure 2, the beverage according to the present invention is a total phenolic acid amount of 16.94 mg / ㎖ while the total amount of phenolic acid of the SOD-removed sample shows 1.99 mg / ㎖ not only red ginseng saponin in antioxidant capacity The role of the mate is also important. That is, the present invention has developed a beverage that exhibits excellent antioxidant capacity, including red ginseng saponin and glutate.
본 발명에 따른 항산화 음료는 홍삼 사포닌을 효소 처리하여 저분자화하여 항산화능이 향상된 홍삼 사포닌과 항산화 물질인 글루메이트를 포함하여 제조함으로써 우수한 자유 라디칼 소거능을 나타내어 자유 라디칼 생성이 주요 원인인 항암요법에 의한 부작용을 억제하는 효과가 크며 자유 라디칼에 의해 발생하는 여러 가지 질병을 방지하는 효과가 있다. 나아가 본 발명에 따른 항산화 음료를 지속적으로 음용함으로써 전체적인 면역력을 증강시킬 수 있는 효과가 있다.Antioxidant beverages according to the present invention are prepared by including red ginseng saponin with improved antioxidant capacity and red ginseng saponin and glutamate, which is an antioxidant substance, to show excellent free radical scavenging ability. It is effective in inhibiting the effects of various diseases caused by free radicals. Furthermore, by continuously drinking the antioxidant drink according to the present invention there is an effect that can enhance the overall immunity.
이상에서 본 발명은 기재된 구체예에서만 상세히 설명되었지만 본 발명의 기술사상 범위 내에서 다양한 변형 및 수정이 가능함은 당업자에게 있어서 명백한 것이다.Although the present invention has been described in detail only in the described embodiments, it will be apparent to those skilled in the art that various modifications and variations are possible within the technical spirit of the present invention.
Claims (3)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020010024720A KR100355012B1 (en) | 2001-05-07 | 2001-05-07 | Antioxidative drink excellent in inhibiting the side effects according to anticancer therapy and the method of manufacturing the same |
JP2002132067A JP2002348245A (en) | 2001-05-07 | 2002-05-07 | Method for changing effective ingredients of ginseng radix rubra into low molecular weight compounds, and method for preparing antioxidizing drink |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020010024720A KR100355012B1 (en) | 2001-05-07 | 2001-05-07 | Antioxidative drink excellent in inhibiting the side effects according to anticancer therapy and the method of manufacturing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020040532A true KR20020040532A (en) | 2002-05-30 |
KR100355012B1 KR100355012B1 (en) | 2002-10-11 |
Family
ID=19709142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020010024720A KR100355012B1 (en) | 2001-05-07 | 2001-05-07 | Antioxidative drink excellent in inhibiting the side effects according to anticancer therapy and the method of manufacturing the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100355012B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100543665B1 (en) * | 2002-10-21 | 2006-01-20 | 정혜경 | Method for producing beer containing antioxidants |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100472098B1 (en) * | 2002-11-15 | 2005-03-11 | 김항종 | Manufacturing method of health drink using black ginseng and black rice |
-
2001
- 2001-05-07 KR KR1020010024720A patent/KR100355012B1/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100543665B1 (en) * | 2002-10-21 | 2006-01-20 | 정혜경 | Method for producing beer containing antioxidants |
Also Published As
Publication number | Publication date |
---|---|
KR100355012B1 (en) | 2002-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Murcia et al. | Evaluation of the antioxidant properties of Mediterranean and tropical fruits compared with common food additives | |
KR101682552B1 (en) | Antioxidant composition comprising red ginseng extracts and berrylike mixtures | |
WO2006090935A1 (en) | Acerola fruit-derived pectin and use thereof | |
KR101936294B1 (en) | Composition comprising for skin-whitening and anti-wrinkling extract of Rumex acetosella L. or extract of Hydrangea serrata | |
KR102105111B1 (en) | Energy drink composition containing increased biological active materials and preparation method thereof | |
Vinayagam et al. | Antioxidant activity of methanolic extracts of leaves and flowers of Nerium indicum | |
CN109200045A (en) | Application and pharmaceutical composition of the Anthocyanin-rich Extract in the pharmaceutical composition of preparation prevention and treatment anthracene nucleus medicament myocardiocyte toxicity | |
CN106665891A (en) | Preparation and use method of snow chrysanthemum polyphenol | |
KR102298042B1 (en) | Composition for antioxidant and anti-inflammatory comprising extract of pepper seeds | |
Conde et al. | Extraction of natural antioxidants from plant foods | |
Ko et al. | Antioxidant and antiradical activities of Wu Ling Shen in a cell free system | |
KR20200145897A (en) | Method for producing extracts of sweet potato with enhanced antioxidative activity and extracts of sweet potato produced by the same method | |
KR101142370B1 (en) | Method for producing fermented solution of mushroom with enhanced antioxidative activity and fermented solution of mushroom produced by the same | |
Guo et al. | Antioxidant and antidiabetic activities of Ulmus davidiana extracts | |
Li et al. | Investigation the nutritional properties of Auricularia auricula pulp fermented with Lactobacillus strains and their effects on gut microbiota | |
KR100760263B1 (en) | Manufacturing method of beverage composition comprising purple-fleshed sweet potato | |
KR100355012B1 (en) | Antioxidative drink excellent in inhibiting the side effects according to anticancer therapy and the method of manufacturing the same | |
CN109549036A (en) | A kind of composite juice and preparation method thereof of collaboration fructus lycii effect | |
KR101546436B1 (en) | The mugwort extracts and method for manufacturing thereof | |
Omoregie et al. | In vitro antioxidant activity and the effect of methanolic extracts of some local plants on nutritionally stressed rats | |
JP2002348245A (en) | Method for changing effective ingredients of ginseng radix rubra into low molecular weight compounds, and method for preparing antioxidizing drink | |
KR102283497B1 (en) | Stick jelly with the effect of antioxidation | |
Marnewick | Antioxidant Properties of Rooibos (Aspalathus linearis)—In Vitro and in Vivo Evidence | |
CN105188419B (en) | The method for preparing muscat pomace extract | |
KR101435872B1 (en) | Cosmetic composition for anti-oxidation and anti-aging comprising Ginseng seeds extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
G15R | Request for early publication | ||
A302 | Request for accelerated examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20110916 Year of fee payment: 10 |
|
LAPS | Lapse due to unpaid annual fee |